Zywie, a pioneer in cardiovascular diagnostics specializing in remote cardiac monitoring through wearable biosensor devices and cloud-based data analytics, has announced a partnership with MedAxiom, a leading provider of organizational performance solutions for the cardiovascular community. “We are proud to welcome Zywie to the MedAxiom community,” said Joe Sasson, PhD, MedAxiom’s chief commercial officer and executive vice president of ventures. “Remote rhythm monitoring is an essential tool for diagnosing cardiac arrhythmias. Zywie’s unique and adaptable solutions provide an exciting opportunity to bring more innovations to our members, educate them on available options and strategies, and advance our shared goal of transforming cardiovascular care.”
Zywie offers various monitors to meet the needs of physicians and patients, including the ZywieNano™ patch, a compact, band-aid-like device that continuously monitors the heart’s electrical activity for up to 30 days. The data collected by the ZywieNano™ patch is sent to Zywie’s cloud-based platform, where it is analyzed by algorithms to provide insights into a patient’s heart rhythm and potential cardiac conditions. Zywie’s capability to analyze electrocardiograms in real-time enables clinicians to proactively address abnormal heart rhythms before they worsen or become life-threatening.
“Zywie is thrilled to announce our partnership with MedAxiom, a leader in cardiovascular organizational performance solutions,” said Latha Ganeshan, CEO of Zywie. “Zywie is committed to advancing patient care through innovative cardiac diagnostics, and this partnership allows us to closely collaborate with MedAxiom’s extensive network and expertise. Together, we are dedicated to delivering enhanced value to patients, healthcare providers, and the broader cardiovascular community.”
Zywie’s platform has demonstrated an ability to increase diagnostic yields and provide more actionable data for healthcare providers compared to standard 14-day monitors. By capturing heart rhythms that might be missed between days 15 and 30, Zywie’s system enhances providers’ ability to accurately identify and diagnose heart-related conditions.
